Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
1.140
+0.030 (+2.70%)
Official Closing Price
Updated: 8:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
313,340
Open
1.110
Bid (Size)
1.060 (1)
Ask (Size)
1.140 (4)
Prev. Close
1.110
Today's Range
1.110 - 1.140
52wk Range
0.8414 - 1.569
Shares Outstanding
174,986,671
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
April 01, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
+4.59%
+4.59%
1 Month
-18.57%
-18.57%
3 Month
+3.64%
+3.64%
6 Month
+0.88%
+0.88%
1 Year
-17.39%
-17.39%
More News
Read More
Lineage Cell Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
March 06, 2024
Via
Benzinga
Lineage Cell Therapeutics: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Earnings Preview: Lineage Cell Therapeutics
November 08, 2023
Via
Benzinga
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
March 18, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
March 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
March 11, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
February 29, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
February 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
February 09, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
February 06, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 01, 2024
Via
Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
January 03, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
January 16, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 29, 2023
Via
Benzinga
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
December 18, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
3 Penny Stocks to Buy for the Next Bull Run
November 11, 2023
Via
InvestorPlace
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
November 01, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
October 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.